Status: Recruiting
Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
This is a Phase 1, first-in-human clinical trial to test a new treatment called ITI-9001 for people with allergies to Japanese Red Cedar (JRC) pollen-a common cause of seasonal allergies in Japan. The main goals are to find out if ITI-9001 is safe, how well people tolerate it, and whether it can trigger helpful immune responses.
Participants needed: 45
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Immunomic Therapeutics, Inc.Updated: Jul 24, 2026Locations: 1
Eligibility criteria
Signed and dated informed consent form (ICF) [+7]
Women of childbearing potential (do not meet inclusion criterion #2) [+4]